Page 23 - Binder2

• Side effects increase as higher doses or additional
drugs are added.
• Hope wanes. The miracle drug becomes just
another failed promise.

Now, the patient is forced to start over. New pre-
authorizations. New side effect profiles. New costs. New
fear. And often, less faith in the next option. Each round
of tolerization erodes the fragile trust between patients and
the therapies they depend on.

Clinicians Are Left Scrambling

Physicians are trained to monitor response, not rejection.
Most are not equipped—scientifically or administratively—
to navigate the intricacies of anti-drug antibody testing or
immune compatibility diagnostics. When a biologic loses
effect, the default is often to escalate dosage, add
immunosuppressants, or switch drugs within the same
class.

But every switch takes time. Every switch introduces new
risks. And every switch contributes to the broader
inefficiency of a system that treats failure as routine,
rather than preventable.

Insurers and Health Systems Bleed Money

For payers, tolerization is a hidden financial sinkhole.
Biologic drugs are some of the most expensive therapies on
the market—ranging from $30,000 to over $500,000 per

21